Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065304 | PMC |
| http://dx.doi.org/10.1016/j.jbo.2022.100431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial.
EClinicalMedicine
January 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Background: The absolute overall survival (OS) improvement with preoperative chemotherapy or chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) patients is controversial and unsatisfactory. We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy.
Methods: Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China.
Synchronous Primary Metastatic Infra-Mammary Accessory Breast Cancer and Ipsilateral Breast Cancer: An Extremely Rare Case Report.
Diagnostics (Basel)
November 2024
Clinic of Surgical Semiotics and Thoracic Surgery-1, Department IX-Surgery-1, "Victor Babes" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Accessory breast cancer cases are rarely reported in the literature. Of the reported cases, the predominantly available ones are those localized in the axillary region. We present here a very rare case of metastatic accessory breast cancer.
View Article and Find Full Text PDFIntracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy.
Mol Pharm
December 2024
Industrial Pharmacy, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of the tumor is almost always guaranteed due to the infiltrative nature of the disease. Moreover, the blood brain barrier imparts an additional layer of complexity by impeding the delivery of therapeutic agents to the tumor, hence limiting the efficacy of systemically delivered drugs.
View Article and Find Full Text PDFSex differences in the pharmacokinetics of anticancer drugs: a systematic review.
ESMO Open
December 2024
Department of Pharmacology, Gustave Roussy, Villejuif, France.
Article Synopsis
- The study highlights that body weight and sex can significantly impact how anticancer drugs are processed in the body, yet the extent of these differences remains unclear.
- A systematic review of 112 studies identified significant pharmacokinetic (PK) differences for 14 out of 99 examined anticancer agents, although no studies currently assess how these differences impact drug efficacy or safety.
- The findings suggest that developing sex-specific dosing strategies for anticancer drugs could improve their risk-benefit ratio for patients.
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer.
ESMO Open
December 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Department of Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Background: This study aimed to investigate the prevalence of claudin 18.2 (CLDN18.2) positivity, with a particular focus on intratumoral heterogeneity, and its association with clinicopathological features in metastatic or unresectable gastric cancer (GC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!